The combination of sintilimab and pemetrexed and platinum chemotherapy is in clinical development for the treatment of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK. Advanced cancers can be locally advanced or metastatic. Locally advanced NSCLC is when the cancer has grown into the tissues surrounding the lung and at the metastatic stage, the disease has already spread from the lungs to other parts of the body. There are currently a number of first line therapies to control advanced or metastatic NSCLC however additional treatment options are needed to improve patient survival.
Sintilimab in combination with pemetrexed and platinum chemotherapy for advanced or metastatic non-small cell lung cancer
The combination of sintilimab and pemetrexed and platinum chemotherapy is in clinical development for the treatment of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK.
Interventions:
Carboplatin (Paraplatin)
, Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)
, Sintilimab (IBI 308; IBI 380; Tyvyt)
Indications:
Non-small-cell lung cancer (NSCLC)
Therapeutic Areas:
Lung and Respiratory Cancer
Year:
2021